Last reviewed · How we verify
Oral iron supplementation
Oral iron supplementation, marketed by the University of Pecs, holds a position in the iron deficiency treatment market. The key composition patent is set to expire in 2028, providing a period of exclusivity that supports current market presence. The primary risk is the lack of reported key trial results and revenue data, which may limit investor confidence and market competitiveness.
At a glance
| Generic name | Oral iron supplementation |
|---|---|
| Also known as | ferrous succinate |
| Sponsor | University of Pecs |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Enrichment of Glutathione Using Gamma-glutamylcysteine Supplementation in Parkinson's Disease Patients. (PHASE1)
- Effect of Intravenous Iron on Quality of Life in Older Patients With Acute Coronary Syndrome (PHASE4)
- Oral Versus Intravenous Iron for Anemia Diagnosed After 34 Weeks of Gestation (NA)
- Patient Blood Management in Cardiac Surgery (NA)
- The Role of Ferric Carboxymaltose in the Treatment of Pediatric Iron Deficiency Anemia in the Emergency Department (PHASE4)
- Iron Supplementation and Anemia After Sleeve Gastrectomy
- Multiple Micronutrient Supplementation (MMS) Iron Dose Acceptability Crossover Trial (PHASE3)
- Multiple Micronutrient Supplementation (MMS) vs IFA Acceptability Crossover Trial (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oral iron supplementation CI brief — competitive landscape report
- Oral iron supplementation updates RSS · CI watch RSS
- University of Pecs portfolio CI